(Q39508383)

12 September 2017

title

Efficacy of voriconazole in a murine model of acute Trypanosoma cruzi infection (English)

1 reference

12 September 2017

0 references

1 reference

1 reference

J E N Gulin

1

1 reference

12 September 2017

M A Eagleson

2

1 reference

12 September 2017

M Postan

3

1 reference

12 September 2017

R A Cutrullis

4

1 reference

12 September 2017

H Freilij

5

1 reference

12 September 2017

F Garcia Bournissen

6

1 reference

12 September 2017

P B Petray

7

1 reference

12 September 2017

J Altcheh

8

1 reference

12 September 2017

language of work or name

English

0 references

publication date

4 December 2012

1 reference

Journal of Antimicrobial Chemotherapy

12 September 2017

published in

1 reference

12 September 2017

volume

68

1 reference

12 September 2017

issue

4

1 reference

12 September 2017

page(s)

888-894

1 reference

Adverse events after the use of benznidazole in infants and children with Chagas disease

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS478

Efficacy of voriconazole in treatment of murine pulmonary blastomycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS478

In vitro and in vivo experimental models for drug screening and development for Chagas disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS478

Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS478

Benznidazole treatment following acute Trypanosoma cruzi infection triggers CD8+ T-cell expansion and promotes resistance to reinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS478

Growth of the laboratory mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS478

Sterol 14-demethylase inhibitors for Trypanosoma cruzi infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS478

Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS478

Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS478

Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS478

In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS478

Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS478

Recent Developments in Sterol 14-demethylase Inhibitors for Chagas Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS478

Hydroxymethylnitrofurazone is active in a murine model of Chagas' disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS478

Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS478

Improving the mouse model for studying the efficacy of voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS478

21 January 2018

Identifiers

DOI

10.1093/JAC/DKS478

1 reference

12 September 2017

1 reference